Medirom Historical Cash Flow
| MRM Stock | USD 1.05 0.04 3.67% |
Analysis of Medirom Healthcare cash flow over time is an excellent tool to project Medirom Healthcare future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 168.3 M or Depreciation of 131.2 M as it is a great indicator of Medirom Healthcare ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Medirom Healthcare latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Medirom Healthcare is a good buy for the upcoming year.
Medirom |
About Medirom Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Medirom balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Medirom's non-liquid assets can be easily converted into cash.
Medirom Healthcare Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Most accounts from Medirom Healthcare's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Medirom Healthcare current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Medirom Healthcare's Change To Netincome is very stable compared to the past year.
Medirom Healthcare cash flow statement Correlations
Click cells to compare fundamentals
Medirom Healthcare Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Medirom Healthcare cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 892K | (2.4M) | (2.4M) | (95.4M) | (25.9M) | (27.2M) | |
| Investments | (45.4M) | 36.3M | (72.9M) | 580.4M | (328.6M) | (312.1M) | |
| Change In Cash | 301.9M | 926.1M | (1.1B) | 234.8M | (499.1M) | (474.2M) | |
| Free Cash Flow | (11.6M) | (440.0M) | (671.0M) | (806.4M) | (767.6M) | (729.2M) | |
| Change In Working Capital | (113.0M) | 267.1M | 1.2M | (49.9M) | 498.8M | 523.7M | |
| Begin Period Cash Flow | 211.7M | 513.6M | 1.4B | 370.6M | 605.5M | 616.9M | |
| Other Cashflows From Financing Activities | (126.1M) | (125.1M) | (176.9M) | (162.3M) | 160.3M | 168.3M | |
| Depreciation | 46.2M | 62.3M | 126.2M | 184.1M | 252.6M | 131.2M | |
| Other Non Cash Items | (7.4M) | (156.7M) | (442.3M) | (968.8M) | (1.4B) | (1.3B) | |
| Capital Expenditures | 19.5M | 73.6M | 113.8M | 120.7M | 135.8M | 94.1M | |
| Total Cash From Operating Activities | 7.9M | (366.4M) | (557.2M) | (685.7M) | (631.7M) | (600.2M) | |
| Change To Account Receivables | (66.9M) | 189.1M | (37.0M) | (222.4M) | 580.7M | 609.7M | |
| Net Income | 17.3M | (539.2M) | (990.7M) | 149.0M | 115.0M | 120.8M | |
| Total Cash From Financing Activities | 332.0M | 1.4B | (427.9M) | 340.1M | 461.2M | 378.2M | |
| End Period Cash Flow | 513.6M | 1.4B | 370.6M | 605.5M | 106.3M | 101.0M | |
| Other Cashflows From Investing Activities | 24.7M | 33.2M | 48.1M | 849.2M | (189.6M) | (180.2M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share (0.15) | Revenue Per Share 1.4 K | Quarterly Revenue Growth (0.06) | Return On Assets (0.04) |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.